Summit 2: Moderator

Ulrich Broeckel, MD
Professor of Pediatrics, Medicine and Physiology and Chief of the Section of Genomics Pediatrics, Medical College of Wisconsin

Dr. Ulrich Broeckel obtained his medical training at the University of Ulm, Germany and obtained his MD from the University of Heidelberg, Germany followed by a residency training in the Internal Medicine and Cardiology. He conducted a postdoctoral fellowship in the Department of Physiology, Medical College of Wisconsin. In 2000, he joined the Medical College of Wisconsin as a faculty member. At the present time, Dr. Broeckel is a Professor of Pediatrics, Medicine and Physiology and Chief of the Section of Genomics Pediatrics. The main research interest of his lab focused on using genetics and genomics for precision medicine focused on cardiovascular diseases as well as the clinical implementation of pharmacogenetics in patient care. At MCW Dr. Broeckel is the technical director of the AGen CAP/CLIA certified lab providing cytogenetics services. He is a member of CPIC as well as PharmGKB. He is also a founder and the CEO of RPRD Diagnostics LLC, a pharmacogenetic testing and precision medicine company in Milwaukee, WI.

Summit 2: Panelists

Kelly E. Caudle, PharmD, PhD, BCPS, FCCP

Kelly E. Caudle, PharmD, PhD, BCPS, is the Clinical Pharmacogenetics Implementation Consortium (CPIC) Co-PI and Director. CPIC provides guidelines that enable the translation of genetic laboratory test results into actionable prescribing decisions for specific drugs. To date, CPIC has published 25 gene-based clinical guidelines. In this position, Dr. Caudle oversees the CPIC guideline development process including the coordination of the guideline writing committees, the guideline evidence reviews, and the writing of the guideline manuscript and supplement. Furthermore, Dr. Caudle is involved in the clinical implementation of pharmacogenetics at St. Jude Children’s Research Hospital.
Timothy T. Stenzel, MD, PhD

Dr. Timothy T. Stenzel, MD, PhD, directs the Food and Drug Administration’s (FDA) Office of In Vitro Diagnostics and Radiological Health. He joined the FDA in July 2018 after a long executive career in both academics as well as industry including oversight of test development for both Clinical Laboratory Improvement Amendment (CLIA) labs and In Vitro Diagnostics (IVD) manufacturers. He completed an MD/PhD, Pathology residency, and Clinical Molecular Genetics fellowship at Duke University prior to joining the Duke faculty and subsequently then moved to industry.

Daryl Pritchard, PhD

Daryl Pritchard, PhD, is the Senior Vice President of Science Policy at the Personalized Medicine Coalition (PMC), where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory, and payment policies that will help advance patient-centered, personalized health care.

Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council (NPC). Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Industry Organization (BIO).

Dr. Pritchard received his PhD and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of Human Genetics (ASHG)/National Human Genome Research Institute (NHGRI) Fellowship in Genetics and Public Policy, where he worked as a health legislative assistant in the U.S. House of Representatives.

Henry “Mark” Dunnenberger, PharmD, BCPS

Dr. Dunnenberger is Director of Personalized Medicine and Pharmacogenomics in the Mark R. Neaman Center for Personalized Medicine at NorthShore University HealthSystem (NorthShore), and leads the various clinical pharmacogenomics implementation projects within the Center. The goal of these projects is to improve the care and health outcomes of NorthShore University HealthSystem patients through pharmacogenomics-based strategies. He joined NorthShore in 2014.

Dr. Dunnenberger leads the Pharmacogenomics Clinic, which serves as part of a system-wide initiative building upon the health system’s strong foundation in genetics and molecular medicine. The Clinic is among only a few across the country, and the first of its kind in the Chicagoland area that pre-emptively
screens patients for responses to medications based on genetic makeup. His clinical expertise and research interests include translating pharmacogenomics into clinical practice, developing information technology solutions for delivering genetic information to both clinicians and patients in a practical manner, and evaluating methods for educating healthcare professionals about pharmacogenetics.

Dr. Dunnenberger has co-authored numerous original publications, including multiple CPIC guidelines. He earned his PharmD from the University of Tennessee Health Science Center College of Pharmacy in 2012. He completed a PGY1 Pharmacy Practice Residency at Mission Hospital in Asheville, North Carolina, and a PGY2 Clinical Pharmacogenetics Residency in the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital in Memphis, Tennessee.

Larisa Cavallari, PharmD, BCPS, FCCP

Larisa Cavallari is an Associate Professor and Director of the Center for Pharmacogenomics at the University of Florida (UF) College of Pharmacy and Director of the UF Health Precision Medicine Program. She received her PharmD degree from the University of Georgia and completed a pharmacy residency at the VA Medical Center in Memphis, Tennessee and a fellowship in cardiovascular pharmacogenomics at UF. Her research involves discovery of genetic associations with drug response, especially in underserved populations; translation of pharmacogenetic evidence into clinical practice; and examination of outcomes with clinical pharmacogenetic implementation. Her research has been funded by the NIH, FDA, American Heart Association, and other awards.

Mary V. Relling, PharmD

Member and Endowed Chair, Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN

Dr. Relling earned her undergraduate B.S. degree from the University of Arizona College of Pharmacy and her doctoral degree from the University of Utah College of Pharmacy. She completed post-doctoral fellowships with Dr. William Evans at St. Jude and with Dr. Urs Meyer at University of Basel. She joined St. Jude as a faculty member in 1988, and in 2003 was named chair of the Department of Pharmaceutical Sciences. She is also a professor at the University of Tennessee in the Colleges of Medicine and Pharmacy.

Her primary interests are in treatment and pharmacogenetics of childhood leukemia and clinical implementation of pharmacogenetic testing. Dr. Relling is part of NIH’s Pharmacogenomics Research Network and co-founder of CPIC, the Clinical Pharmacogenetics Implementation Consortium. She has published over 400 original scientific manuscripts. She was elected to the Institute of Medicine in 2009.